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Abstract: The enzymatic co-polymerization of modified nucleoside triphosphates (dN*TPs 
and N*TPs) is a versatile method for the expansion and exploration of expanded chemical 
space in SELEX and related combinatorial methods of in vitro selection. This strategy can 
be exploited to generate aptamers with improved or hitherto unknown properties. In this 
review, we discuss the nature of the functionalities appended to nucleoside triphosphates and 
their impact on selection experiments. The properties of the resulting modified aptamers  
will be described, particularly those integrated in the fields of biomolecular diagnostics, 
therapeutics, and in the expansion of genetic systems (XNAs). 
Keywords: aptamers; modified nucleoside triphosphates; polymerases; SELEX; therapeutic 
oligonucleotides; chemically modified nucleic acids; synthetic genetic polymers 
 
1. Introduction 
Aptamers are single-stranded DNA or RNA molecules that bind to specific targets with high affinity 
and are often considered to be the nucleic acids’ pendant of antibodies [1,2]. The advent of aptamers 
was propelled by the discovery of SELEX [3–5] (Systematic Evolution of Ligands by Exponential 
enrichment) and related combinatorial methods of in vitro selection. In SELEX, large populations of 
oligonucleotides (typically ~1014 molecules of up to 100 nucleotides in length) are screened for their 
potential binding affinity for a defined target (see Figure 1) [6,7]. In this chemical variant of Darwinian 
evolution, the initial population of oligonucleotides is bound to the selected target and only the species 
capable of binding are retained, PCR-amplified, and used for subsequent rounds of selection [8]. By 
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modulating various parameters of the selection experiment, including the nature of the target, the length 
of the randomized region of the original library, and the selection stringency, a broad array of 
multifunctional aptamers can be obtained. Moreover, since the inception of the traditional SELEX 
method in 1990, numerous modifications and variants have been developed to fit the choice of the target, 
the different conditions, and include new technologies such as high-throughput sequencing methods and 
microfluidics [9,10]. 
 
Figure 1. Schematic representation of the SELEX strategy for the identification of  
DNA aptamers. 
While natural (unmodified) nucleic acids are capable of folding into intricate three-dimensional 
structures and bind to their target by shape complementarity, the lack of chemical modifications present 
in these functional nucleic acids was soon recognized to be detrimental for their potential in vivo 
applications. Indeed, as is the case for any wild-type DNAs and RNAs, aptamers are prone to nuclease 
degradation and are sensitive to the chemical (e.g., basic media, divalent metal cations) or physical (e.g., 
heat) environment [11–13]. Furthermore, nucleic acids are rather functionality deprived biopolymers, 
especially when compared to their proteinaceous counterparts [14]. This dearth of functional groups 
limits aptamers in their capacity to form specific interactions with more demanding targets and might 
preclude the formation of hydrogen bonding patterns or hydrophobic pockets as seen in antibodies and 
proteins in general. These limitations were recognized shortly after the advent of SELEX and modified 
aptamers can be obtained either (1) by introducing modifications into the scaffold of selected aptamers 
via standard solid-phase synthesis or (2) by using modified nucleoside triphosphates (dN*TPs and 
N*TPs) directly in the selection process [2,15–17]. 
Molecules 2015, 20 16645 
 
 
In this context, this review will focus specifically on the burgeoning field of modified aptamers.  
A strong emphasis will be given on aptamers obtained by in vitro selection with modified nucleoside 
triphosphates (dN*TPs and N*TPs) to increase their binding efficiencies, selectivities, and their 
pharmacokinetic properties. Moreover, their application for therapeutic and diagnostic purposes will be 
discussed as well as aptamers made of synthetic genetic polymers (XNAs) [18–20]. Many excellent 
review articles [2,21] have addressed the post-synthetic modification and labelling of aptamers and this 
vast topic is beyond the scope of the present review. 
2. Modified Aptamers for Therapeutic and Diagnostic Applications 
A large number of distinctive properties renders aptamers attractive candidates for therapeutic 
applications [22,23]. For example, their high affinity and specificity for their targets is comparable to 
that of proteinaceous antibodies, however, unlike the latter, their size is smaller (8–15 kDa) and they 
lack immunogenicity. Furthermore, access to aptamers has been facilitated by recent progress in standard 
automated solid-phase synthesis and larger quantities can be synthesized at low cost (less than 200 $/g 
for unmodified aptamer; up to 1 kg scale) [24,25]. Modulation of the nature of the target in the selection 
protocol allows for the generation of aptamers against a great variety of targets ranging from small 
molecules and peptides to proteins and cells. Interestingly, their inhibitory action can be reversed by an 
antidote, a feature that holds great potential for drug design [26,27]. Indeed, the shape and three-dimensional 
structure of an aptamer can be distorted by binding to a polymer or complementary oligonucleotides, which 
in turn alters the activity of the aptamer [28–30]. This approach has recently been used to modulate the 
spatiotemporal activity of an anti-nucleolin aptamer both in vivo and in vitro by using a complementary 
oligonucleotide antidote equipped with photocleavable linkages [30]. In a slightly different approach, 
aptamers can be selected against known drugs and their binding affinity then serves as the basis for the 
antidote effect. In this context, an aptamer was selected against bivalirudin, an anticoagulant drug, and 
shown to cause a dose-dependent regeneration of the clotting activity in the presence of bivalirudin [31]. 
Taken together, aptamers are very potent and versatile ligands and display a multitude of favorable 
assets for their use as diagnostic tools and therapeutic agents. Currently, one anti-VEGF aptamer has 
been approved for the treatment of age-related macular degeneration [32], whilst numerous aptamers are 
in pre-clinical studies and clinical trials for a broad variety of applications including gene therapy [33–35], 
immunotherapy [36,37], cancer therapy [27,38], and the development of imaging agents [39,40]. 
However, despite their numerous favorable characteristics, aptamers suffer from several drawbacks: 
(i) while aptamers are stable under long-term storage conditions, their biostability is compromised by 
rapid renal filtration and by the presence of nucleases; (ii) nucleic acids have a rather depleted chemical 
arsenal and thus lack functional groups that could enhance the binding affinity to more difficult targets 
(e.g., single enantiomers of small organic molecules or glycosylated proteins) and favor the formation 
of additional potential interactions with the target; (iii) with the exception of the 3′- and 5′-termini, the 
chemical modification of aptamers via solid-phase synthesis can lead to a depletion of the binding 
affinity; (iv) some selection experiments yield aptamers with poor binding affinities as a result of either 
lack of functionalities to sustain strong binding or a competition between amplification in SELEX and 
functional fitness of the sequences. In order to (partially) alleviate these shortcomings, modifications 
located at the level of the sugar unit, the nucleobase, or the backbone of the constituting nucleotides  
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can be introduced using dN*TPs as vectors in selection experiments. However, for dN*TPs to be 
acceptable candidates in SELEX, they obligatorily must be good substrates for polymerases, and the 
resulting modified sequences need to serve as templates for the conversion into wild-type DNA under 
PCR conditions [11,41]. Recent advances in protein engineering and the development of the 
compartmentalized self-replication (CSR) and compartmentalized self-tagging (CST) strategies [42,43], 
have allowed for the evolution of numerous polymerases with expanded substrate tolerance [44,45]. 
Therefore, finding conditions for the successful polymerization of particular (d)N*TPs can readily be 
achieved by assessing the substrate acceptance using a pool of engineered and/or evolved polymerases. 
The importance and the nature of the functionalities appended on the nucleoside triphosphates along 
with their use in SELEX will be highlighted through some recent implementations presented in the pages 
to follow. 
2.1. Sugar Modifications 
Early modifications of the scaffold of aptamers paralleled progresses attained in the field of antisense 
research and focused mostly on the 2′-position of the (deoxy-)ribosesugar unit (Figure 2) [1,46]. Initial 
efforts included 2′-amino pyrimidines 1 [15,47–52], 2′-fluoro pyrimidines 2 [16,50,53–55] and  
2′-methoxy nucleotides 3 [56,57]. All these selection experiments led to the isolation of 2′-modified 
aptamers that displayed good binding affinities (Kd values in the low nM down to the pM range) and strong 
nuclease resistance. In most cases, the isolated aptamers were converted post-selection into shorter and 
more potent species by solid-phase synthesis. 
 
Figure 2. Chemical structures of 2′-modified nucleotides used in selection experiments to 
generate aptamers with enhanced pharmacokinetic properties: 2′-amino-NTPs 1, 2′-fluoro-NTPs 
2, 2′-methoxy-NTPs 3, and 4′-thio-NTPs 4. 
The first use of N*TPs in a Darwinian in vitro selection experiment was reported by Jayasena et al. in 
1994. The use of 2′-NH2-pyrimidine NTPs in the selection experiment instead of their natural counterparts 
resulted in the isolation of anti-human neutrophil elastase aptamers with good binding affinities (Kd values 
in the low nM range) and nuclease resistance (t1/2 = 20 h in human serum compared to ≤8 min for the 
unmodified oligonucleotide) [47]. However, despite initial success (e.g., an anti-bFGF (basic fibroblast 
growth factor) aptamer that displayed a high specificity and a very strong binding affinity (Kd = 35 pM) 
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for its target [15]), 2′-NH2-pyrimidines are only rarely used nowadays due to problems encountered during 
solid-phase synthesis and their preference for the C2′-endo ribose conformation [11,58]. Nevertheless, in 
a very elegant approach, Bugaut et al. used the 2′-amino-modification as a synthetic handle for the 
introduction of transient functionalities via imine formation, thus combining aspects of SELEX and 
dynamic combinatorial chemistry (DCC). This approach was succesfully applied to the selection of  
anti-TAR modified RNA aptamers [59]. 
On the other hand, the other two modifications (2′-methoxy and 2′-fluoro) have become the most 
widely used N*TPs for the in vitro evolution of aptamers. The combined use of 2′-fluoro-pyrimidines 
N*TPs and wild-type purine NTPs in a selection experiment, followed by the post-selection modification 
and conversion of the unmodified ribonucleotides to 2′-methoxy modifications, led to the isolation, 
development, and ultimately the approval of pegaptanib (Macugen®, Pfizer, New York, NY, USA), the 
only aptamer-based drug currently approved by the FDA [32,54]. Pegaptanib is a 27 nucleotide long 
RNA aptamer that is administered for the treatment of neovascular age-related macular degeneration 
(AMD). It binds to the abundant isoform of the human vascular endothelial growth factor (VEGF) with 
very high affinity (Kd = 49 pM), and thus inhibits the interaction with its receptors [24,27]. 
In a more recent study, Li et al. selected RNA aptamers targeting the four members of the epidermal 
growth factor receptor (EGFR) family starting from an initial RNA pool obtained by the T7 RNA 
polymerase-mediated transcription with natural and 2′-fluoropyrimidine-modified NTPs [60]. The initial 
selection experiment led to the isolation of one particular aptamer that displayed a strong binding affinity 
to human EGFR (Kd ~40 nM) and was much shorter than the initial randomized region (51 vs. 62 
nucleotides, respectively). This sequence was then used as a template for a second in vitro selection 
experiment which led to the isolation of aptamer E07. The E07 aptamer had a strong binding affinity for 
the wild-type receptor comparable to that of the natural substrate EGF (Kd = 2.4 nM) and was shown to 
block in vitro the EGF-stimulated phosphorylation of the receptor and thus, inhibited the cell proliferation 
while being also efficiently internalized into EGFR-expressing cells. Finally, aptamer E07 also showed 
a rather high propensity (Kd = 36 nM) to bind to the mice form of EGFR (mEGFR) which has 88% 
homology with the human form [60]. Similarly, a whole cell-SELEX experiment on human non-small-cell 
lung cancer cells (NSCLC) with 2′-fluoropyrimidine-modified NTPs allowed Esposito et al. to isolate a 
rather short (39 nucleotides) aptamer that could inhibit the epidermal growth factor receptor (EGFR) 
through tightly binding to the lung cancer cell line A549 (Kd = 38 nM) and could discriminate these 
targets from H460 cells [61]. This aptamer was further shown to induce selective cell death both in vitro 
and in vivo [61]. Both selection experiments underscore the usefulness of using modified nucleoside 
triphosphates to generate nuclease-resistant aptamers (the stability of 2′-fluoro-siRNAs has been estimated 
to be >1 day [62]) that effectively compete with the natural ligand and could induce apoptosis. 
The same 2′-fluoro-modification was used by Svobodova et al. to generate RNA aptamers against the 
prostate-specific antigen (PSA), a glycoprotein involved in prostate cancer [63]. One particular aptamer 
(S2) showed a moderate affinity to the intended target since it bound to PSA with a Kd value of 630 nM 
and displayed an 11 nM limit of detection in an apta-PCR assay [63]. The isolated aptamers were also 
tested for their potential application in both diagnostics and therapeutics, providing an alternative to the 
well-studied A10 aptamer, another 2′-F-RNA aptamer binding to the prostate-specific membrane antigen 
(PSMA) [64]. 
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An interesting approach employed in vivo SELEX [65] to identify 2′-fluoropyrimidine modified RNA 
aptamers that were capable of penetrating the blood-brain barrier (BBB) [66]. A 2′-fluoro-modified RNA 
pool was injected into mice (via tail injection) and the RNA present in the brain was isolated and amplified. 
After 22 rounds of selection, sequence convergence was observed and one particular sequence, aptamer 
A15, dominated the RNA population [66]. This aptamer was then shown to specifically accumulate in the 
brain, rather than in the kidney or liver. Moreover, aptamer A15 was further modified with 2′-methoxy 
residues to increase the nuclease resistance and tested for brain penetration via in vitro internalization 
assays. It was shown that the aptamer first targets the endothelial cells before entering the brain 
parenchyma of the A15-injected mice. The biodistribution of the aptamer demonstrated positive signals 
in numerous brain regions including the cortex, hippocampus, cerebellum, and striatum suggesting 
successful permeation. 
All in all, this versatile modification has been widely exploited over the last years by many groups 
for various targets (Table 1) and has underlined its significance among other common modifications. 
Table 1. Summary of the recently generated aptamers using the 2′-fluoro modification. 
Aptamer 
Name 
Aptamer Target 
Kd Value 
(nM) 
Reference 
E07 Epidermal growth factor receptor (EGFR) 2.4 [60] 
CL4 Epidermal growth factor receptor (EGFR) 10 [61] 
S2 Prostate-specific antigen (PSA) 630 [63] 
A15 Brain penetrating aptamer - [66] 
R-F t2 NS5B replicase, essential for the replication of hepatitis C virus (HCV) 2.6 [67] 
Gint4.T Platelet-derived growth factor receptor β (PDGFRβ) 9.6 [68] 
GL21.T Transmembrane tyrosine kinase receptor (RTK) Axl 12 [69] 
G-3 C-C chemokine receptor type 5 (CCR5) 110 [70] 
C26-50 N-methyl-D-aspartate (NMDA) receptor ion channel 120 [71] 
Apt1 CD44, a cell-surface glycoprotein that serves as a cancer stem cell marker 81.3 [72] 
B-68 HIV-1Ba-L glycoprotein 120 52 [73] 
GL44 Human U87MG glioma cells 38 [74] 
RNA 14-16 p68 RNA helicase, which is involved in colorectal cancer 13,8 [65] 
FAIR-6 Interleukin-6 receptor (IL-6R) 40.9 [75] 
CD28Apt2, 
CD28Apt7 
CD28 costimulatory receptor for the activation of T lymphocytes 
40,  
60 
[76] 
9C7 OX40 costimulatory receptor 1.7 [77] 
αV-1, β3-1 αV and β3 subunits of integrin αVβ3 2.7, 6.5 [78] 
Unlike 2′-fluoro- and 2′-amino-modified N*TPs, 2′-methoxy-N*TPs have rarely been engaged in 
selection experiments, despite the very favorable properties of polymers equipped with this particular 
functional group [56,57]. Most aptamers containing 2′-OMe-units, including pegaptanib (vide supra), 
stem from post-selection engineered sequences obtained from in vitro selections that combine  
2′-fluoro-pyrimidine N*TPs and wild-type 2′-OH-purine NTPs [56]. The main reason for this relative 
scarcity resides in the rather poor substrate acceptance of the bulkier 2′-OMe-N*TPs by the wild-type 
T7 RNA polymerase, especially when compared to the smaller 2′-fluoro- and 2′-amino-modifications [46]. 
On the other hand, the combination of engineering of mutants of the T7 RNA polymerase [79–82] and 
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the discovery of optimized conditions [56], have enabled the enzymatic synthesis of 2′-OMe-RNA libraries 
for their use in in vitro selection experiments. In this context, a direct in vitro selection experiment using 
the four modified 2′-OMe-N*TPs along with a small fraction of natural GTP culminated in the isolation 
of a potent anti-VEGF aptamer (Kd = 1 nM) [56]. More recently, a combination of three 2′-OMe-N*TPs 
and the lone, natural dCTP were used in a selection experiment for the generation of an aptamer that 
binds to the polypeptide tissue factor pathway inhibitor (TFPI) involved in the regulation of the extrinsic 
coagulation pathway [83]. The resulting aptamer bound selectively and tightly (Kd = 2.8 nM) to TFPI and 
was shown to correct thrombin generation in the bleeding disorders hemophilia A and B. 
In a very interesting approach, coined cell-uptake selection, three 2′-OMe-N*TPs and the lone, natural 
GTP were used for the identification of aptamers that could both recognize different cell lines of prostate 
cancer cells and internalize directly into cells [84]. Indeed, Farokhzad et al. rationalized that selecting 
for aptamers that displayed the highest affinity and selectivity for their targets, for instance by lowering 
the temperature [85], would not necessarily yield aptameric species capable of being internalized by 
cells, which is an important prerequisite for potential in vivo applications. Consequently, the modified 
RNA library was first incubated with counter-selection cell lines and the bound species were discarded. 
The unbound sequences that remained in the supernatant of the counter-selection step were then 
incubated with the desired cell lines (PC3 and LNCaP cells) at 37 °C. A cell lysis then allowed for the 
extraction of the RNAs that were capable of internalization [84]. In addition, the stringency of the selection 
was gradually increased by diminishing both the incubation time and the number of the desired cell lines 
and by introducing a randomization of the various populations by mutagenic PCR. After 12 rounds of 
selection, aptamers that recognized and internalized specifically into both cell lines could be identified. 
Finally, a targeted nanoparticle (NP) encapsulating a chemotherapeutic agent against prostate cancer 
(docetaxel) was connected to one of the selected 2′-OMe-modified aptamers via maleimide-thiol chemistry 
and the resulting hybrid construct was then shown to significantly improve the cytotoxicity in the target 
cells by a combination of aptamer-mediated internalization and a release of the drug [84]. 
Other sugar modifications have also been utilized in selection experiments for the isolation of 
aptamers. For instance, in the early 2000s, the group of Matsuda introduced a modification by replacing 
the 4′-oxygen atom of the sugar unit with a sulfur atom (structure 4 in Figure 2) [86]. The modification 
was first used for the synthesis of the 4′-thiouridine (4′-thio-UTP) and 4′-thiocytidine (4′-thio-CTP) 
triphosphates which were then used in the in vitro selection of anti-thrombin thioRNA aptamers. The 
resulting 4′-thio-modified aptamer bound to the thrombin target with high affinity (Kd = 4.7 nM) and 
displayed a 50-fold increase in resistance to RNase A as compared to wild-type RNA [86]. This initial 
selection experiment with two modified 4′-thio-N*TPs was then followed by an optimization of the  
in vitro transcription conditions using the set of four modified NTPs which in turn allowed for the selection 
of a fully-modified RNA aptamer against the same target [87]. The most potent aptamer resulting from 
this selection experiment displayed a similar binding affinity to thrombin as the partially modified aptamer 
(Kd = 7.2 nM) but presented no sequence homology with the latter [87]. 
The 4′-thio-modification has also been explored on the DNA level and shown to be compatible with 
enzymatic synthesis [88,89]. Similarly, selenium modified dNTPs and NTPs have also been synthesized 
and evaluated for their substrate acceptance by DNA polymerases and T7 RNA polymerase, respectively.  
In particular, 2′-methylseleno-NTPs [90,91] and 4′-selenothymidine triphosphate (SeTTP) [92] were shown 
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to be readily accepted by their respective polymerases but have not been engaged in any selection 
experiments so far. 
Finally, other sugar-modified nucleoside triphosphates such as LNA, HNA, TNA, and other XNAs 
have been used as building-blocks for the generation of modified aptamers (vide infra) [20]. 
2.2. Backbone Modifications 
The backbone of a nucleoside triphosphate can be modified at any of the three phosphorous atoms or 
the bridging oxygens, but in order to serve as a vector for the introduction of chemical functionalities 
into nucleic acids, the modifications must be located at the α-phosphorous atom. In this context, 
phosphorothioate linkages are well established modifications in antisense technology due to their 
chirality, their stability against nucleases, and their ability to internalize into cells without the help of any 
carrier [93]. In the context of aptamer selections, the group of Gorenstein has used a two-step selection 
strategy to obtain thioaptamers as drug carriers that specifically bind to E-Selectin, whose overexpression 
has been associated with many inflammatory diseases [94]. The selection protocol involved a single  
α-thio-dATP nucleotide and resulted in the isolation of aptamer ESTA-1 that bound to its target with 
high affinity (Kd = 47 nM) without recognizing the other members of the selectin protein family (a Kd of 
13 μM was determined for P-selectin, while no binding to L-selectin could be observed). In addition, the 
nuclease resistant ESTA-1 inhibited the adhesion of leukocytes (HL-60 cell line) through its binding to 
E-selectin, which recognizes the carbohydrate ligand sialyl Lewis X expressed by the HL-60 cells [94]. 
The same group has also previously reported on the selection of mono-thio aptamers against the nuclear 
factor kappa B (NF-κB; Kd = 0.8 nM) [95], aptamers acting as inhibitors of the RNase H domain of  
HIV-1 reverse transcriptase (Kd = 70 nM for binding to HIV-1 RT) [96], and against CD 44 antibodies 
(Kd in the 180–295 nM range) [97], while a fully thio-modified aptamer targeted against an envelope 
protein of dengue-2 virus was obtained [98]. 
Recently, a new method for the incorporation of small drug-like molecules at the C5-position of the 
nucleobase of uridines on a complete monothiophosphate backbone-substituted aptamer in order to 
obtain next-generation (X-aptamers) with greatly enhanced nuclease resistance and binding affinities 
has been reported [99]. The group used this method to introduce an ADDA (N-acetyl-2,3-dehydro-2-
deoxyneuraminic acid) molecule that binds to the hyaluronic acid binding domain of CD44 antibodies 
(CD44-HABD) and the selected aptamer displayed a binding affinity of less than 10 nM. This work 
paves the way for the isolation of aptamers with expanded chemical functionalities and combined 
characteristics of drug molecules, proteins, and nucleic acids. 
Even though other backbone modified triphosphates have been reported, including α-P-seleno-TTP [100], 
α-P-methyl-TTP [101,102], and α-P-borano-α-P-thio-TTP [103], none have been employed in the 
context of SELEX, probably due to their low acceptance by polymerases. However, a notable exception is 
the α-P-borano-modification. Indeed, single α-P-borano-modified triphosphates (α-B-UTP and α-B-GTP) 
were used in the selection of boronated aptamers against ATP [104]. Surprisingly, the selection with  
α-B-UTP resulted in a population of oligonucleotides that bore very little sequence homology to that 
obtained with α-B-GTP. 
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2.3. Base Modifications 
2.3.1. General Base-Modifications 
Modifications of the nucleobases are mostly located at the C5-position of the pyrimidines and the N7 
of 7-deaza-purines (see Figure 3), as these positions have been shown to be good substrates for polymerases 
and well tolerated in the major groove of duplexes [105–108]. The introduction of functionalities at the 
level of the nucleobase might increase the contact interactions of oligonucleotides and their intended 
targets and might create additional secondary structures that are not accessible to wild-type nucleic acids 
and thus enhance the binding affinity. This concept was exploited in an early selection experiment where 
Latham et al. isolated an anti-thrombin aptamer (albeit with a rather poor binding affinity) using a dUTP 
equipped with a hydrophobic (pentynyl) residue (dUpenTP 5, Figure 4a) [109]. After this initial example, 
other selection experiments using base-modified (d)NTPs were reported, including the use of the 
photoactivatable 5-iodo-UTP to generate an anti-HIV-1 Rev protein aptamer [110] and the inclusion of 
positively charged residues on dUTP [111] and UTP [112] for the isolation of aptamers selective for ATP. 
 
Figure 3. Chemical structure and numbering of the purine and pyrimidine nucleobases 
exemplified for ATP and UTP. 
(a) 
Figure 4. Cont. 
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(b) 
Figure 4. (a) Chemical structures of some base-modified dN*TPs used in aptamer selection 
experiments; (b) Target molecules camptothecin and thalidomide. 
More recently, Li et al. introduced a boronic acid moiety (B-TTP 6, Figure 4a) into thymidine-5′-
triphosphate and selected for aptamers that could bind to fibrinogen through specific recognition of the 
glycosylation site [113]. The isolated aptamers all displayed dissociation constants that lay in the low 
nM range, while the unmodified DNA pool of the last selection round displayed a ~1000 fold lower 
affinity (average Kd = 5 μM). Binding of the aptamers occurred via interactions of the boronic acid 
moieties and the glycan structures present in fibrinogen, clearly underscoring the usefulness of this 
modification [113]. 
Imaizumi et al. utilized a DNA library generated by primer extension reaction including a dUTP 
equipped with an adenine residue tethered to the C5 site of the nucleobase (dUadTP 7, Figure 4a) [114]. 
The introduction of this additional nucleobase was thought to convey additional hydrogen bonding 
patterns and stacking interactions to the modified DNA population. The resulting modified pool was 
used to isolate aptamers that would bind to the antitumor agent camptothecin derivative 1 (CPT1, Figure 4b). 
After 11 rounds of selection, a very potent 70-mer aptamer (CMA-70) could be isolated, which was 
further converted to a shorter 59-mer version (CMA-59) by sequence refinement. Both CMA-70 and 
CMA-59 displayed strong binding efficiencies to CPT1 with dissociation constants of 39 and 86 nM, 
respectively. What is more, this aptamer also demonstrated an improved binding affinity compared to 
aptamers obtained via a selection with natural dNTPs (Kd = 1.1 μM). Moreover, substitution of the 
modified nucleotides either by wild-type dT units or by a modified dU analog missing the adenine unit 
led to a marked decrease (~1500 fold less) in binding affinity compared to CMA-59, again highlighting 
the potential of using base modifications in in vitro selection experiments for the generation of aptamers 
capable of selectively detecting and binding to small molecules. A few years earlier, the same group 
published a significant paper, where they selected a modified aptamer (using THMTP 8, Figure 4a) capable 
of binding only to the (R)-isomer of thalidomide (Figure 4b), pointing out the high enantioselectivity 
modified aptamers can exhibit [115]. 
The 5-ethynyl-modified dUTP (EdUTP) was revealed to be a pivotal tool in a variant of in vitro 
selection coined SELMA (SELection with Modified Aptamers) [116]. The alkyne units that are 
incorporated into the dsDNA hairpin library via primer extension serve as synthetic handles for the 
grafting of glycans (Man4 or Man9) onto the nucleic acid scaffold (Figure 5) [117]. The resulting 
modified glyco-ssDNA strands could then be displaced by a second primer extension reaction using  
all-natural dNTPs and a primer annealed inside the hairpin loop. This strand displacement also causes a 
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physical separation between phenotype (i.e., the glycol-DNA construct that can act as the aptameric 
species) and the genotype (i.e., the wild-type dsDNA that encodes the sequence information corresponding 
to the aptamers) [117]. Subsequently, the modified library is subjected to a standard in vitro selection 
protocol which includes binding to the desired target, PCR amplification of the genotype DNA, and 
conversion to an enriched population of hairpin ssDNAs (Figure 5). SELMA was employed to identify 
glycol-DNA aptamers that could recognize the monoclonal antibody 2G12 which is known to bind to 
mannose-rich glycans on the HIV envelope protein gp120, thus neutralizing various HIV strains [117–119]. 
An initial SELMA experiment using a population with 25% of potential glycan positions in the 
randomized library and a rather short Man4 unit led to the identification of aptamers that bound to 2G12 
with dissociation constants in the 200–300 nM range [117]. In order to improve the moderate binding 
affinities, a SELMA selection that included a longer Man9 construct and randomized library that 
contained fewer potential glycan anchoring sites (7% or 15%) was carried out and resulted in the 
isolation of a truncated aptamer with an improved binding affinity (Kd = 150 nM) [118]. Finally, when 
the selection was carried out at 37 °C rather than at room temperature, but by keeping the same selection 
set-up, aptamers with binding affinities in the 1.7–16 nM were identified [119]. Interestingly, these 
aptamers had only three to five glycosylation sites, all of which were necessary for the binding activity, 
which univocally occurred at the gp120 binding site of 2G12 [119]. 
 
Figure 5. Schematic overview of the SELMA method. Figure adapted from reference [118].  
Carbohydrates were also the target of a selection experiment that utilized a dUTP analog equipped 
with a positively charged amino group at the C5 position of the nucleobase (THMTP 8, Figure 4a), with 
the intent of increasing the binding affinity to the negatively charged silalyllactose [120]. The modified 
DNA pool was incubated with biotinylated silalyllactose bound to magnetic particles, and after 13 rounds 
of SELEX, an aptamer with low binding affinity was isolated (Kd = 4.9 μM). In a conceptually related 
experiment, an arginine-modified dUTP was engaged in an in vitro selection experiment with the 
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negatively charged glutamic acid as the target [121]. Despite low dissociation constants (in the high 
micromolar range), the isolated aptamers displayed some enantioselectivity since they could recognize 
the D- from the L-isomer. 
Vaught et al. synthesized C5-modified carboxamid dUTP derivatives to enable the attachment of a 
range of hydrophobic groups (for instance, Bn-dU and Trp-dU, see Figure 6) [122]. After testing the 
enzymatic incorporation of these dU*TPs by polymerases, they selected for modified DNA aptamers 
against the tumor necrosis factor receptor super family member 9 (TNFRSF9), a protein involved in 
cancer and inflammatory diseases. The binding affinity of their modified aptamer (Kd = 0.5–9 nM) 
surpassed that of a previously published RNA aptamer against the same target (Kd = 40 nM). It was this 
work that laid the foundations for the development of novel aptamers termed SOMAmers. 
Other various base-modified dN*TPs [123] and N*TPs [124] have been recently evaluated for their 
capacity at serving in selection experiments, but have not been used for the generation of modified 
aptamers and thus will not be covered in this review. 
 
Figure 6. Examples of the 5-modified deoxyuridine triphosphates used as building blocks for the 
generation of SOMAmers [58,122,125,126]. R groups: Bn-dU: benzyldeoxyuridine; dT*: methyl-
dU (thymidine); iB-dU: isobutyldeoxyuridine; Th-dU: 2-thieno-methyl-propyl-deoxyuridine; 
FBn-dU: 4-fluoro-benzyl-deoxyuridine; Pe-dU: 2-Phenyl-ethyl-deoxyuridine; Pp-dU: 3-Phenyl-
n-propyl-deoxyuridine; Tyr-dU: tyrosyl-deoxyuridine; Nap-dU: 1-naphtyldeoxyuridine; MBn-
dU: 3,4-methyl-dioxy-benzyl-deoxyuridine; Bt-dU: 2-(3-benzo(b)thiophenyl)-ethyldeoxyuridine; 
2Nap-dU: 2-naphtyldeoxyuridine; Ne-dU: 2-(1-naphtyl)-ethyldeoxyuridine; 2NE-dU: 2-(2-
naphtyl)-ethyldeoxyuridine; Trp-dU: Tryptophanyldeoxyuridine. 
2.3.2. SOMAmers 
Despite the successful results standard SELEX has presented us with, there are still some protein targets 
that remain inaccessible to high affinity aptamers as a result of the limited chemical diversity of nucleic 
acids. What is more, a lower and conservative approach estimates that the human proteome contains at 
least 10,000 proteins, present at varying concentrations and involved in numerous interactions [127].  
In an effort to develop aptamers displaying higher affinities that could be used to explore the human 
proteome, aptamers were equipped with protein-like side chains with the intent of reducing the koff values 
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(SOMAmers; Slow Off-rate Modified Aptamers) and were shown to tightly and specifically bind to their 
targets [128]. An impressive array of dN*TPs has been prepared for the generation of SOMAmers and 
most of these nucleoside triphosphates comprise hydrophobic residues such as naphtyl- or benzyl-groups 
(Figure 6) which can increase both the number and the strength of hydrophobic interactions between 
nucleic acids and the corresponding targets, thus partially mimicking the binding mode of antibodies and 
other proteins. These interactions and the deep involvement of the modified nucleotides were confirmed 
by crystal structures of several SOMAmer-protein complexes [126,129], and univocally demonstrated 
by the low- to sub-nanomolar dissociation constants that are regularly observed with SOMAmers [130]. 
In addition to lowering the koff rates (down to ~10−5·s−1) [130], and thus increasing the affinity and 
selectivity [131], SOMAmers also present an improved resistance to nucleases [58]. While the selection 
protocol for SOMAmers largely followed that devised for other modified aptamers, an additional step was 
included in order to ensure slow koff rates. This step involved incubation of the SOMAmer-target protein 
complexes with a large excess of a non-specific polyanionic competitor (e.g., dextran sulfate) [128]. 
Finally, those SOMAmers along with novel designed technologies (SOMAscan assay) facilitate the 
simultaneous detection of various proteins in the blood serum and have been widely applied in the 
discovery of disease biomarkers [132]. Indeed, within five years, SOMAmers specific for over 3000 human 
proteins have been identified with unique properties that have the potential to be employed in the fields 
of therapeutics and diagnostics [58,126]. 
2.4. Spiegelmers 
The concept of using L-nucleosides to foster mirror-image aptamers (termed Spiegelmers [133,134]) 
arose almost 20 years ago, but its impact can be seen at present as three Spiegelmers are currently 
undergoing clinical investigations. They are synthesized by L-nucleoside phosphoramidites after the 
corresponding D-aptamer against the mirror-image target of interest has been identified through 
conventional in vitro selection methods [135]. This two-step protocol is necessary since L-nucleoside 
triphosphates are not accepted by RNA and DNA polymerase [136], a fact that is at the origin of their 
use as potent antiviral agents [137]. However, progress in polymerase evolution [19,138] and the 
generation of ribozymes recognizing heterochiral nucleic acids or nucleotides [139], spawn hope for the 
discovery of enzymes capable of catalyzing the polymerization of L-nucleoside triphosphates which in 
turn would allow circumventing this protocol. Moreover, due to the enantioselectivity rules that govern 
nature, Spiegelmers are endowed with high stability against nuclease degradation and make promising 
drug candidates. 
All three Spiegelmers currently in clinical trials have been developed by NOXXON Pharma in 
Germany [140]. Olaptesed pegol (NOX-A12) is evaluated in two parallel Phase II trials for the treatment 
of chronic lymphocytic leukemia and refractory multiple myeloma by targeting the CXCL-12 chemokine. 
Lexaptepid pegol (NOX-H94), an anti-hepcidin L-RNA aptamer, is tested for anemia induced by chronic 
inflammation, while emapticap pegol (NOX-E36) binds to the monocyte chemoattractant protein 1 
(MCP-1) that promotes inflammation in type-2 diabetes. 
Apart from the above mentioned Spiegelmers, the group at NOXXON has recently been interested in 
two additional targets. NOX-G15 is a mixed DNA/RNA mirror-image aptamer that binds to the glucagon 
and improves the glucose tolerance in models of type 1 and type 2 diabetes [141]. This could ultimately 
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result in decreased insulin demand for the disease. On the other hand, NOX-S93 targets the signaling 
lipid S1P (sphingosine-1-phosphate), involved in cancer, autoimmune diseases, as well as fibrosis [142]. 
The L-RNA aptamer showed high affinity (Kd = 4.3 nM) and good selectivity and successfully inhibited 
the IGF-1 induced angiogenesis by neutralizing the S1P. 
Furthermore, Sczepanski et al. developed an L-RNA aptamer to target the HIV-1 trans-activation 
responsive (TAR) RNA [143]. In this significant work, the authors demonstrated that the strong binding 
activity (Kd = 100 nM) and consequently the inhibition of the D-RNA target by this L-RNA aptamer 
occurred by recognition of a distal loop by means of tertiary interactions rather than Watson-Crick 
pairing. This mode of interaction could account for even greater specificity thus adding up to the features 
that make aptamers suitable for therapeutic applications [143]. Consequently, L-RNA aptamers are 
alluring and promising candidates for therapeutic applications since they confer high binding affinities, 
good selectivities, high nuclease resistance, and they are not confined to Watson-Crick base-pairing 
recognition motifs [140]. 
3. XNAs and Expanded Genetic Systems 
The quest for answers regarding the evolution of prebiotic life has brought about a series of studies 
on the chemical etiology of RNA [144]. In this context, it is believed that the four-letter genetic alphabet 
evolved as a compromise between replication fidelity, informational complexity, and evolution and 
adaption capacities [20]. However, expanding the genetic alphabet beyond the canonical Watson-Crick 
base-pair (and thus increasing the informational complexity) is an alluring goal for the development of 
functional nucleic acids with improved properties [145–147], the creation of systems expressing proteins 
based on non-standard amino acids [148], and even for the generation of semi-synthetic organisms [149,150]. 
In a key contribution, Kimoto et al. introduced a third base pair in the process of DNA replication by 
using two unnatural nucleotides (the Ds:Px pair) that exclusively pair with each other (Figure 7) [146]. 
The selection experiments yielded aptamers that could bind to VEGF-165 and INF-γ with very high affinity 
(Kd values comprised between 1.69 pM and 0.12 nM), one of the few examples where modified aptamers 
seem to have an improved affinity compared to the natural ones. However, the unnatural base Ds had to 
be placed at predetermined positions in order to facilitate the cloning and sequencing methods, a limitation 
that could be resolved in the years to come. Similarly, the Z:P pair (Figure 7), presenting an alternate 
hydrogen bonding pattern and adopting a Watson-Crick-like geometry [151], was used in an in vitro 
selection experiment using an expanded ACGTZP sequence space for the generation of aptamers that can 
selectively recognize HepG2 liver cancer cells [152]. Application of 13 rounds of cell-LIVE (laboratory 
in vitro evolution; a variant of SELEX which allows for sequence evolution during the selection process) 
resulted in the isolation of modified aptamers presenting dissociation constants in the 10–200 nM range. 
The species bearing Zs and Ps were found to be the better binders compared to unmodified species and 
the presence of the modified nucleotides was necessary to maintain the high binding affinity [152]. The 
use of base-modified dN*TPs in the context of an expansion of the genetic alphabet culminated with the 
creation of an E. coli strain where the hydrophobic base-pair system d5SICS:dNaM (Figure 7) was 
stably incorporated into a plasmid, and for the first time, resulted in the in vivo replication of an unnatural 
base-pair [150]. 
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Figure 7. The structures of the unnatural Ds:Px, P:Z, and d5SICS:dNaM base pairs. 
The development of new genetic polymers via Darwinian evolution is not restricted to base-modifications 
but can also encompass chemical alterations to the sugar moiety [18–20]. Indeed, sugar-modifications 
(i.e., beyond the initial 2′-alterations brought to the ribose unit, vide supra) can obviously confer nuclease 
resistance to oligonucleotides, but, more importantly, can lead to orthogonal artificial nucleic structures 
(XNAs, Xeno-Nucleic Acids) that are capable of storing information and that support enzymatic synthesis, 
and thus lead to an expansion of the chemical repertoire (Figure 8) [20]. For instance, the structural key 
feature of hexitol nucleic acid (HNA) is the 1′,5′-anhydrohexitol backbone, which is at the origin for the 
versatility of HNA (i.e., stable duplexes are formed with HNA, DNA, and RNA) and the possibility of 
forming alternate base pairs (e.g., HNA-A/HNA-A) [153]. Recently, an engineered DNA polymerase was 
shown to support both DNA-dependent HNA polymerization and HNA-dependent DNA polymerization 
with high fidelity [145]. This fact was then exploited to evolve aptamers against two targets, the  
trans-activating response RNA (sTAR) and the hen egg lysozyme (HEL) [145]. After eight rounds of  
in vitro selections, HNA aptamers with high affinities for the respective targets were obtained: Kd values 
of 28–67 nM when sTAR was the target, and 107–141 nM for anti-HEL aptamers [145]. This approach 
could also be compatible with other chemistries including FANA, CeNA, ANA, TNA, and LNA 
modifications of the sugar scaffold (Figure 8) since polymerases accepting these triphosphates as substrates 
have been engineered (but have not been engaged in aptamer selections) [145]. What is more, the potential 
of these engineered polymerases to tolerate those modifications was also used to explore catalytic systems, 
namely XNAzymes catalyzing the scission of ribophosphodiester linkages or acting as ligases [147]. 
Similarly, TNA nucleoside triphosphates were shown to be good substrates for an engineered 
polymerase (Therminator DNA polymerase) under primer extension reactions [154,155]. In addition, an 
in vitro selection scheme was devised, where the transcribed TNA population was directly connected to 
its DNA template, thus connecting phenotype and genotype, respectively [156]. However, some limitations 
became apparent when a TNA aptamer selection was undertaken: [157] the polymerization reaction comes 
to a halt when repeating G nucleotides are present in the library and diaminopurine triphosphate should be 
used instead of TNA-ATP (tATP) to ensure high transcription yields. Notwithstanding these limitations, 
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an anti-thrombin TNA aptamer (Kd ~ 200 nM) could be selected by using a library that does not contain 
any cytosine nucleotides, clearly showing that TNAs are capable of Darwinian evolution [157]. 
 
Figure 8. Xeno Nucleic Acids (XNAs) and their structures. 
As mentioned previously, the LNA structure is another example of sugar modification that has gained 
significant attention since its advent [158,159]. Due to its nuclease resistance and the unprecedented 
affinity of LNA oligonucleotides for complementary DNA and RNA sequences, LNA has served as an 
important tool in many oligonucleotide-based applications including antisense and antigene therapy, 
diagnostics, and biotechnology [160–162]. The compatibility of LNA-triphosphates with RNA- and 
DNA-polymerases has been demonstrated [163] and was the fundament for the establishment of reliable 
protocols for in vitro selection using this modification [164,165]. Based on these findings, a selection 
experiment using a single LNA-TTP led to isolation of anti-thrombin aptamers with high binding 
affinities (Kd values in the low nM range) [166]. More recently, two LNA aptamers have been proposed, 
one targeting the VEGF as a potential therapeutic agent against breast cancer [167], whilst the second 
one aims at the inhibition of cellular CD73, a cell surface protein overexpressed in many solid tumors [168]. 
Moreover, Hagiwara et al. used a random library containing two diverse modifications, namely LNA 
and 2′-Fluoro nucleic acid (FNA) to select chimeric DNA aptamers by capillary electrophoreses SELEX 
(CE-SELEX) [169]. In their work, they demonstrated that the DNA strands could adopt an A-type 
conformation more usually encountered in RNA. Their results confer new paradigms to achieve not only 
chemical but also structural diversity of nucleic acids. 
Finally, nucleoside analogs combining dual base- and sugar-modifications have also been evaluated 
for their potential to serve in the creation of XNA modified systems and organisms [170]. Indeed, the 
 
Molecules 2015, 20 16659 
 
 
isoguanine:5-methylisocytosine (isoG:isoMeC) pair was grafted on the HNA scaffold and the base-pairing 
properties and the acceptance of polymerases were determined. These modifications were also studied 
for their effect on base-recognition and DNA synthesis in vivo [170]. Similarly, base-modified LNAs have 
been shown to be compatible with DNA polymerases under primer extension reaction conditions and with 
the T7 RNA polymerase to generate RNA transcripts, but have not been used in selection experiments [171]. 
4. Conclusions and Future Directions 
Aptamers have emerged as a promising class of therapeutics due to a variety of properties including 
their small size, the lack of immunogenicity, and their high affinity and selectivity for their targets. Barriers 
regarding their susceptibility to nucleases have successfully been addressed by the use of modifications 
post-selection, but in many cases, resulting in a reduced affinity compared to the natural aptamers. An 
attractive solution to this drawback is the inclusion of modified nucleoside triphosphates directly in the 
selection experiments. Indeed, this not only circumvents the need for tedious post-selection engineering 
of the sequences that is often associated with a loss in activity, but also allows for the introduction of 
functional groups that might increase the affinity by creating new interactions with the target and 
generate differential folding and structural patterns. 
The advent of engineered polymerases that tolerate a broad array of substrates along with recent 
progress in synthetic organic chemistry has seen a massive expansion of the chemical space that can be 
explored in SELEX experiments. The positive reflection of these progresses on functional nucleic acids 
is the emergence of numerous synthetic aptamers with improved properties, including high affinity to 
the target (i.e., in the low nM to pM range), strong biostability, improved pharmacokinetic properties, 
recognition of more challenging targets (e.g., glycoproteins and single enantiomers of small organic 
molecules), and improved bioavailability (e.g., crossing of the BBB or internalization). However, 
generating modified aptamers with SELEX can sometimes be a more challenging procedure since it is a 
rather time-consuming process with variable success rates. These technical impediments are partially 
alleviated by the emergence of new SELEX strategies such as LIVE [172], cell-SELEX [8], or other 
methodologies for the selection of modified functional nucleic acids [173]. 
Nevertheless, some aptamers like the SOMAmers have managed to find their way around those issues 
and reach the industrial threshold encouraging the exploitation of novel structural and functional 
diversities. So far, the use of modifications in diagnostics has been limited only to the biomarker discovery. 
It could be interesting to also see their contribution as in vivo aptasensors or imaging agents for targets 
that are inaccessible to natural aptamers. 
Taken together, recent progress made in the generation of modified aptamers by selecting with 
dN*TPs and N*TPs bodes well for the future of aptamers as therapeutic agents and diagnostic tools. The 
synergy between the design of target-specific modifications on the nucleoside triphosphate(s) and the 
application of a suitable selection protocol will certainly contribute positively to an increase in the 
number of aptamers in clinical trials, propelling more modified aptamers to join pegaptanib in the rank 
of FDA-approved nucleic acid-based drugs. 
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